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Abstract. Human papillomavirus-positive (HPV+) oropha-
ryngeal squamous cell carcinoma (OPSCC) has increased in 
incidence and has a much better prognosis than HPV-negative 
(HPV-) OPSCC with radiotherapy alone, but exactly why 
is unknown. The present study therefore aimed to further 
examine the sensitivity and possible changes in gene expres-
sion of several HPV+ and HPV- OPSCC, including various 
novel cell lines, upon ionizing irradiation (IR). Previously 
established HPV+ UM-SCC-47, UPCI-SCC-90, CU-OP-2, 
CU-OP-3 and HPV- UM-SCC-4, UM-SCC-6, UM-SCC-74a, 
UM-SCC-19 and newly established CU-OP-17 and CU-OP-20, 
characterised here, were subjected to 0-6 Gy. Surviving frac-
tions of each cell line were tested by clonogenic assays, and 
irregularities in cell cycle responses were examined by flow 
cytometry, while changes in gene expression were followed by 
mRNA sequencing. HPV+ OPSCC cell lines showed greater 
variation in sensitivity to ionizing irradiation (IR) and tended 
to be more sensitive than HPV- OPSCC cell lines. However, 
their IR sensitivity was not correlated to the proportion 
of cells in G2 arrest, and HPV- cell lines generally showed 
lower increases in G2 after IR. Upon IR with 2 Gy, mRNA 
sequencing revealed an increase in minor HPV integration 
sites in HPV+ cell lines, and some changes in gene expression 
in OPSCC cell lines, but not primarily those associated with 
DNA repair. To conclude, HPV+ OPSCC cell lines showed 
greater variation in their sensitivity to IR, with some that were 
radioresistant, but overall the HPV+ OPSCC group still tended 
to be more sensitive to IR than the HPV- OPSCC group. In 
addition, HPV+ OPSCC lines were more frequently in G2 as 
compared to HPV- cell lines, but the increase in G2 arrest upon 
IR in HPV+ OPSCC was not correlated to sensitivity to IR. 
Increases in minor HPV integration sites and changes in gene 
expression were also demonstrated after irradiation with 2 Gy.
Introduction
The incidence of human papillomavirus-positive (HPV+) 
tonsillar and base of tongue squamous cell carcinomas 
(TSCC/BOTSCC), the major subsites of oropharyngeal squa-
mous cell cancer (OPSCC), (but not other OPSCC subsites) 
is still increasing in most western countries (1-4). Together 
they account for an increasing proportion of head and neck 
squamous cell carcinomas (HNSCC), especially in countries 
where smoking, a main HNSCC risk factor is decreasing (4,5).
Patients with HPV+ TSCC/BOTSCC usually respond well 
to treatment and have better long-term survival compared to 
HPV- TSCC/BOTSCC and HNSCC in general, irrespective if 
they receive radiotherapy alone, or radio-chemotherapy (i.e. 
80 vs. 40-50% 5-year overall survival) (1,5-9). However, over 
recent decades, treatment for HNSCC, as well as for HPV+ 
TSCC/BOTSCC, has gradually been intensified with radio-
therapy and induction or concomitant chemotherapy, and the 
numbers of side effects have increased (5). Most likely this 
intensified therapy could be de‑escalated for most patients 
with HPV+ TSCC/BOTSCC, but to facilitate this, greater 
knowledge of the responsiveness of these tumours to different 
treatment strategies is required, both through clinical and 
preclinical studies (10).
Previous in vitro studies have investigated response to 
ionizing irradiation (IR) in a range of HNSCC cell lines. 
These studies describe differences in sensitivity to IR 
correlating with HPV status (11-17). Some of these reports 
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suggest an association between a greater intrinsic cellular 
radio-sensitivity and increased survival in HPV+ HNSCC cell 
lines (11-13). However, in these studies the numbers of HPV+ 
OPSCC cell lines have been limited, making it difficult to 
assess the generalizability of these observations (11-17). There 
is a clear need to assess the correlation between HPV status 
and radiosensitivity in a greater number of cell lines, but HPV+ 
OPSCC cell lines are relatively scarce and are notoriously 
difficult to establish.
In 2014, to our knowledge, there are eight published 
HPV+ HNSCC cell lines: UPCI-SCC-90, UPCI-SCC-154, 
UPCI-SCC-152, UM-SCC-104, UM-SCC-47, 93-VU-147T, 
UD-SCC-2 and UT-SCC-45 (11-18). In 2018, we established 
and characterised two new HPV+ cell lines CU-OP-2 and 
CU-OP-3 (18). In this report, two additional cell lines CU-OP-17 
and CU-OP-20 have been derived and characterised. We have 
used these 4 novel lines, and 6 established OPSCC lines to 
investigate the effects of IR on surviving fraction (SF), cell 
cycle distribution, and global transcription patterns, similar to 
studies performed by others (11-13). In addition, circos plots 
were established, to identify possible changes in HPV integra-
tion sites.
Materials and methods
Patients, cell lines, and sample collection. Five HPV+ and five 
HPV- OPSCC cell lines were included in this study.
To derive novel lines, TSCC biopsies were obtained, 
during the diagnostic procedure (where ultimately diagnosis 
is finalised by multidisciplinary meetings) from patients, prior 
to treatment at Cardiff and Vale University Health Board, in 
concordance with Ethical and NHS R&D approval (reference 
number 13/WA/0002), by written consent. The derivation 
of HPV+ CU-OP-2 and CU-OP-3 has been described previ-
ously (18). CU-OP-17 and CU-OP-20, described here for the 
first time, were established using the same processes (18), 
and were shown below to be HPV- and HPV+ respectively. 
The identity of all CU-OP cell lines included in this report 
was established by short tandem repeats (STR) as described 
previously for CU-OP-2 and CU-OP-3 (18), and by Public 
Health England (Promega, Southampton, UK) for CU-OP-17 
and CU-OP-20. The characteristics of the patients from which 
CU-OP-17 and CU-OP-20 were derived and their tumours are 
shown in Table I. For CU-OP-2 and CU-OP-3 these details 
have been published previously (18). All CU-OP cell lines 
were grown on 60 Gy irradiated J2 3T3 feeder layers (a kind 
gift from Dr Sally Roberts, University of Birmingham, UK) in 
GMEM medium with 10% FBS, and further details have been 
described previously (18).
HPV+ UM-SCC-47 and HPV- UM-SCC-6, UM-SCC-19, 
UM-SCC-74a and UM-SCC-4 were obtained from Professor 
Thomas Carey at the University of Michigan USA. HPV+ 
UPCI-SCC-90 was purchased from Deutsche Sammlung 
von Mikoorganismen und Zellkulturen (DSMZ), Leibniz, 
Germany. All these cell lines are described in the data base 
https://web.expasy.org/cellosaurus/. These cell lines were 
all cultured in DMEM (Sigma-Aldrich; Merck KGaA), with 
1% L-glutamine, 100 U/ml of penicillin, and 100 µg/ml 
streptomycin and 10% foetal bovine serum (Sigma-Aldrich; 
Merck KGaA).
Human epithelial keratinocytes (HEKn) were purchased 
from Thermo Fisher Scientific, Inc. and grown as described 
previously in EpiLife media (18).
All cell lines were tested for absence of mycoplasma, 
by standardised PCR, using the Venor®GeM detection kit 
(Minerva Biolabs), which is specific to the highly conserved 
16s rRNA coding region, thereby detecting a wide range of 
mycoplasma species.
HPV PCR. The presence of HPV in CU-OP-17 and CU-OP-20 
was confirmed by a bead‑based multiplex assay for 27 HPV 
types as described in detail previously (19). This PCR uses 
BSG5+/G6+ primers targeting the L1 region, as well as primers 
targeting the HPV16 E6 region, and includes the analysis 
of all high-risk HPV types using a PCR-based bead-based 
multiplex-assay on a MagPix instrument (Luminex Corp.) as 
previously described (19). A mean fluorescence intensity (MFI) 
value above 1.5x background + 8 for specific HPV primers 
were considered as HPV-positive as previously described (19).
Clonogenic assay and analysis. Cells were cultured at low cell 
densities, more specifically in ranges of 2,500‑12,500 cells per 
plate on 6‑cm culture dishes (VWR) and incubated at 37˚C with 
5% CO2 for 24 h. Cell density per cell line, was defined before 
the initiation of clonogenic assays. Cell density, was defined by 
individual cell line density tests (using ranges of cells between 
1,000-20,000 cells/well lasting for ~10-15 days depending on 
the cell line. After 24 h the cells were irradiated with 0-6 Gy 
(Gammacell-1000 MDS Nordion; a caesium-137 source) and 
the media were changed after 7 days. The assays were stopped 
10-15 days later (depending on the growth of the cell lines) and 
the cells stained with crystal violet, and the colonies counted 
using a Colony counter (ColonyDoc-It Imaging Station, UVP).
Data analysis and statistical evaluation of clonogenic 
assay. All experiments were performed in triplicates. The 
plating efficiency (PE) and survival fraction (SF) of each 
cell line per IR dose was calculated. Cells were classified 
as radiosensitive SF <0.40 or radio-resistant SF >0.40 as 
described before (20). The mean value was calculated and 
standard deviations (SD) are indicated as error bars. Statistical 
evaluation was performed using GraphPad Prism (GraphPad 
Version 7, GraphPad Software), by using a two-way ANOVA 
with a Sidak post‑test. Strength of significance is indicated 
as follows: *P<0.05, **P<0.01, ***P<0.01 and ****P<0.001). ns 
stands for not significant.
Flow cytometry
Sample preparation and collection. Cells were cultured 
without feeder cells in 6-cm culture dishes (VWR) and treated 
with 0-6 Gy 24 h after seeding. Untreated cells were collected 
24 h after seeding, while irradiated cells were collected 8, 24 
and 48 h after treatment. Approximately 500,000 cells/cell line 
were fixed in 1 ml of 70% ethanol in fluorescence‑activated cell 
sorting (FACS) tubes and stored at ‑20˚C for at least 1 h. Cells 
were then washed with PBS, incubated with 100 µl of RNase A 
(10 µg/ml) (Sigma‑Aldrich; Merck KGaA) for 45 min at 37˚C, 
centrifuged at 270 x g, and resuspended in 200 µl propidium 
iodide (PI) solution (50 µg/ml) (Sigma-Aldrich; Merck KGaA) 
and incubated for 15 min at 37˚C.
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Cell cycle measurement and statistical analysis. The PI-stained 
cells were analysed using a BD Accuri C6 (BD Biosciences) 
low‑pressure flow cytometer (absorbance 488 nm). Data were 
extracted as FCS files and the cell cycle distribution was 
analysed with FlowJo analysis software (version 10; FlowJo 
LLC), using the cell cycle tool, based on the Watson pragmatic 
algorithm (21). For each cell cycle phase the mean value was 
calculated based on a total of three experimental runs. Each 
IR dose and time point were compared to the non-treated 
sample ‘time zero’, to quantify changes in cell cycle distri-
bution after IR treatments. Excel 2016 was used to generate 
100% stacked bar charts. Statistical analysis was performed 
in GraphPad Prism 7 (GraphPad Software, Inc.) using a 
two-way ANOVA with a Sidak post-test to the panel of cell 
lines (treatment dose and time points). Strength of signifi-
cance is indicated as follows: *P<0.05, **P<0.01, ***P<0.01 and 
****P<0.001). ns stands for not significant.
mRNA sequencing
Experimental set up. Cells (untreated and 2 Gy) were collected 
24 h after treatment and RNA was extracted with QiaAMP 
Mini kit (Qiagen) according to the manufacturer's instructions.
Library preparation. Library preparation and validation 
for mRNA sequencing was performed through a commer-
cial service/collaboration with Wales Gene Park (Cardiff 
University, UK). Library preparation, including depletion of 
ribosomal RNA was carried out using the Illumina® TruSeq® 
Stranded Total RNA with Ribo-Zero Gold™ kit (Illumina Inc.) 
according to the instructions of the manufacturer.
Sequencing and data analysis. A 75-base paired-end dual 
index read format was used on the Illumina® HiSeq2500 
in high-output mode by the Wales Gene Park (Cardiff 
University, UK). Sequencing data were analysed by the 
bioinformatics service by Dr Peter Giles at the Wales 
Gene Park (Cardiff University, UK). Trimmed reads were 
mapped against a combined human sequence genome hg19 
and an HPV16 genome reference sequence NC_001526 
using STAR (Alex Dobin, Git Hub) to generate circos plots. 
For both exons and transcripts, gene expression counts were 
calculated, using Subread feature Counts Version 1.5.1 (22). 
Data were visualised using The Integrative Genomics 
Viewer (IGV) downloaded from the Broad Institute (23) 
and Geneview software (written by Dr Peter Giles of the 
Wales Gene Park).
Differential gene expression. The DEseq2 analysis tool was 
used to identify differentially expressed genes (statistical 
analysis of count matrices for systematic changes between 
conditions) (24). For multiple testing and false discovery 
issues, the generated P-values were corrected using the FDR 
method (25). The data are shown in heatmaps in 3 colour 
patterns, where green represents underexpressed (compared 
to median); black represents values approximately median 
expression; and red represents overexpressed values.
Human viral fusion transcript plots (circos plots). Circos plots 
were used to visualise and identify human (hg19) and viral 
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Results
Derivation of novel OPSSC cell lines CU‑OP‑17 and CU‑OP‑20. 
Explant cultures using fresh primary biopsies from two patients 
with TSCC were attempted as described previously (18). In addi-
tion, and the identity of the cell lines CU-OP-17 and CU-OP-20 
to the tumour biopsies was confirmed by STR. Details of these 
two patients and their tumours are shown in Table I. The HPV 
status of the biopsy and resulting cell line was assessed by 
PCR-based bead-based multiplex-assay on a MagPix instru-
ment and the obtained MFIs calculated as described above: 
CU-OP-20 tested positive for HPV-16; CU-OP-17 was HPV-. 
TP53 status assessed by RNA sequencing was considered as 
being wild-type in both cell lines.
Surviving fraction (SF) of HPV+ and HPV‑ 
OPSCC cell lines after ionising irradiation (IR). The sensi-
tivity of the panel of 10 OPSCC cell lines to IR was assessed 
using clonogenic survival assays. The SFs of all OPSCC cell 
lines to 0.5-6 Gy respectively are shown in Fig. 1, and Tables II 
and III, respectively.
Special focus was put on an indicated clinically relevant 
dose of 2 Gy (20), which identified three HPV+ OPSCC cell 
lines UM-SCC-47 (SF=14.1) UPCI-SCC-90 (SF=28.3) and 
CU-OP-20 (SF=20.4) and only one HPV- OPSCC cell line 
UM-SSC-19 (SF=32.4) as radiosensitive, Tables II and III, 
respectively. All other cell lines were by definition radioresis-
tant (20). Furthermore, for 2 Gy, HPV+ OPSCC cell lines tended 
to be more sensitive and showed a wider variability in SF 
values (14.1-60.4, mean 33.6) than the HPV- OPSCC cell lines 
(32.4-71.8, 51.4) P=0.0754 (Mann-Whitney one-tailed t-test as 
conducted in (13) (Fig. 1, Tables II and III, respectively).
There were significant differences in SF within the HPV+ 
and HPV- groups after IR with 2 Gy. HPV+ UM-SCC-47 and 
CU-OP-20 were more radiosensitive to 2 Gy compared to 
CU-OP-2 and CU-OP-3, and UPCI-SSC-90 was more radiosen-
sitive than CU-OP-3 (for all at least P<0.05) (Fig. 1A). Among 
the HPV- OPSCC cell lines, UM-SCC-19 was more radio-
sensitive than CU-OP-17 (P<0.0001) (Fig. 1B). Fig. 1C shows 
the SF values in more detail after treatment with 2 Gy for all 
OPSCC cell lines as well as HEKn. Fig. 1C demonstrates that 
HPV+ OPSCC cell lines have a variable sensitivity to IR, as well 
as an evident overlap with HPV- OPSCC cell lines, but still tend 
to be more radiosensitive than the HPV- OPSCC cell lines.
Effects of IR on cell cycle distribution in HPV+ and HPV‑ 
OPSCC cell lines. To gain insight into the mechanisms 
underlying the differences in sensitivity to IR, the cell lines 
were treated with IR and the effects on cell cycle distribution 
were assessed by flow cytometry. IR induced cell cycle effects 
primarily on HPV+ OPSCC as compared to HPV- OPSCC 
and mainly in the proportion of cells in G2, and the data are 
presented in detail below. 
Changes in G2 arrest in HPV+ OPSCC cell lines. No signifi-
cant changes were observed in cell cycle distribution 8 h 
after 2-6 Gy for any cell line. However, after 24 h (2 Gy), a 
significant increase in cells in G2 phase was observed for two 
HPV+ OPSCC cell lines: UM-SCC-47 (the most radiosensitive 
line, P=0.0135) and CU-OP-3 (the most radioresistant line, 
P=0.0075) (Fig. 2A and E). For the 6 Gy treatment after 24 h, 
all HPV+ OPSCC cell lines showed a significant increase in 
G2 arrest (UM-SCC-47, P<0.0001; UPCI-SCC-90, P<0.0001; 
CU-OP-20, P=0.0004; CU-OP-2, P=0.0019; and CU-OP-3, 
P<0.0001) (Fig. 2). After 48 h post 6 Gy treatment the propor-
tion of cells in G2 was generally reduced. In UM-SCC-47, 
UPCI-SSC-90 and CU-OP-2, the reduction in G2 fraction was 
significant (P<0.05) (Fig. 2A‑C).
Changes in G2 arrest in HPV‑ 
OPSCC cell lines. Compared to untreated controls, at 2 Gy 
after 24 h, a significant increase in cells in G2 was observed in 
one HPV- OPSCC cell line, UM-SCC-4, P=0.0222 (Fig. 3C). 
With 6 Gy after 24 h, an increase in G2 arrest was only 
observed in two lines, and these were the two most IR resistant 
ones of the five HPV- cell lines: UM-SCC-4, P=0.0027 and 
CU-OP-17, P=0.0052 (Fig. 3C and E). It was notable that in 
Figure 1. Surviving fraction (SF) of HPV+ and HPV- cell lines following 
ionizing irradiation. (A) SF of HPV+ cell lines. At 2 Gy the difference in 
survival between the most radiosensitive (UM-SCC-47) and the most radio-
resistant (CU-OP-3) cell lines was significant (****P<0.0001). Additional 
significant differences are noted only in the text of the results section. ns, 
not significant. Error bars indicate standard deviations. (B) SF of HPV- cell 
lines to IR. At 2 Gy the difference in survival between the most radiosensitive 
(UM‑SCC‑19) and the most radioresistant (CU‑OP‑17) cell lines was signifi-
cant (****P<0.0001). Additional significant differences are noted only in the 
text of the results section. ns, not significant. Error bars indicate standard 
deviations. (C) SF after treatment with 2 Gy for all HPV+ and HPV- SCC 
cell lines and the human epithelial keratinocyte cell line HEKn. As example 
of statistical significance, the comparison of UM‑SCC‑47 to CU‑OP‑17 is 
presented (****P<0.0001). For this specific comparison a one‑way ANOVA 
with a Sidak post-test was used. HPV, human papillomavirus.
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contrast to the HPV+ lines, neither UM-SCC-4, nor CU-OP-17 
showed a reduction in G2 fraction after 48 h.
Changes in G1 in HPV+ and HPV‑ 
OPSCC cell lines. Roughly, 50-60% of HPV+ and HPV- OPSCC 
cells were initially in G1, and few changes occurred 8-48 h 
after IR (Figs. 2 and 3). Compared to controls, with 2 Gy after 
8 h, decreases in the proportion of cells in G1 were noted in 
HPV+ UM-SCC-47, P=0.0031; HPV- UM-SCC-4, P<0.0001; 
and HPV- UM-SCC-74a, P=0.0168; (Figs. 2A and 3C and D), 
and this was the case after 24 h for CU-OP-17, P=0.0402; 
(Fig. 3E), while instead an increase in G1 was seen at 24 h 
in UM-SCC-74a, P=0.0037; (Fig. 3D). At 6 Gy, after 24 h, 
a decrease in G1 could be seen for HPV+ UM-SCC-47, 
P<0.0001; and UPCI-SCC-90, P<0.0001; (Fig. 2A and B) and 
HPV- UM-SCC-19, P=0.0312; and UM-SCC-4, P=0.0305 
(Fig. 3A and C).
Changes in S‑phase in HPV+ and HPV‑ 
OPSCC cell lines. Compared to untreated controls some 
changes in the proportion of cells in S phase occurred early 
(8 h), but not later (24-48 h) after IR in both HPV+ and HPV- 
OPSCC cell lines (Figs. 2 and 3). Compared to controls, with 
2 Gy after 8 h an increase in the proportion of cells in S-phase 
was observed in HPV+ UM-SCC-47; P=0.0002; (Fig. 2A) 
and HPV- UM-SCC-4, P<0.0001; (Fig. 3C). Compared to 
controls, with 6 Gy after 8 h, HPV+ UM-SCC-47, P=0.0004; 
UPCI-SCC-90, P=0.0123; CU-OP-2; P=0.0144; (Fig. 2A-C) 
and HPV- UM-SCC-4, P=0.0061; (Fig. 3C) showed increases 
in the proportion of cells in S-phase.
No changes in the cell cycle after IR of HEKn. No significant 
changes were observed in the cell cycle of HEKn between the 
non-treated samples and the 2 Gy and 6 Gy samples (8, 24 and 
48 h) (Fig. S1). One representative flow cytometry plot of each 
cell line is presented in Figs. S2 and S3.
Influence of IR on HPV integration. RNA sequencing 
was used to identify the presence on human: Viral fusion 
transcripts before and after treatment with 2 Gy IR. This 
data was visualised using circos plots, which demonstrated 
fusion transcripts as described previously for UM-SCC-47, 
UPCI-SCC-90, CU-OP-2 and CU-OP-3 (18). The main 
integration sites were: UM-SCC-47-chromosome 3 to 
TP63 from E6/E7; UPCI-SCC-90-C9orf156 (chromo-
some 9 open reading frame 156 and 200 bp before FOXE1 
Table III. Surviving fraction (SF) of HPV- OPSCC cell lines and HEKn after treatment with 0.5-6 Gy.
 Surviving fraction (%)
 --------------------------------------------------------------------------------------------------------------------------------------------------------
 HPV- cell line  Non-cancer cell
 sensitive to IR HPV- cell lines resistant to IR line response to IR
 ---------------------------- ------------------------------------------------------------------------------------------------------------------- -----------------------------------
Treatment dose (Gy) UMSCC-19 UMSCC-6 UMSCC-74a UMSCC-4 CU-OP-17 HEKn
0.5 81.7 87.4 85.3 92.3 94.3 79.8
1 69.1 62.9 70.1 85.1 84.2 70.6
2a 32.4 44.9 47.7 60.1 71.8 32.7
4 15.5 11.3 8.9 15.6 28.8 17.6
6 3.8 2.4 0.9 2.3 10.3 1.6
aSF, <40% defined as sensitive to IR according to (20).
Table II. Surviving fraction (SF) of HPV+ cell lines after treatment with 0.5-6 Gy.
 Surviving fraction (%)
 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HPV+ cell
 HPV+ cell lines sensitive to IR lines resistant to IR
 --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
Treatment dose (Gy) UMSCC-47 UPCI-SCC-90 CU-OP-20 CU-OP-2 CU-OP-3
0.5 78.4 72.5 66.8 93.6 90.5
1 44.4 48.5 46.9 64.1 83.3
2a 14.1 28.3 20.4 44.7 60.4
4 1.3 7.5 3.8 12.2 19.1
6 0.3 1.7 0.8 7.2 12.1
aSF <40% defined as sensitive to IR according to (20). IR, ionizing irradiation; HPV, human papillomavirus.
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from E7; CU-OP-2-chromosome 10 to E2 (YME1L1 gene at 
introns 6 and 7); CU-OP-3-chromosome 20 at the gene CEBPB 
(CCAT/enhancer binding protein β) (Fig. S4) (18). Novel 
minor HPV integration sites were identified for CU‑OP‑20, but 
a high incidence of fusion transcripts above 5 mapped reads, 
as described previously (18) were not disclosed (Fig. S4). 
Treatment with 2 Gy did not change the main integration 
sites of UM-SCC-47, UPCI-SCC-90, CU-OP-2 and CU-OP-3 
(Fig. S4). However, the frequency of additional minor chromo-
somal integration sites per chromosome increased after 2 Gy 
IR, i.e. for the radiosensitive lines: UM-SCC-47, from 3 to 16; 
UPCI-SCC-90, from 17 to 20; and CU-OP-20; from 7 to 20; as 
well as for the radioresistant lines: CU-OP-3, from 6 to 21 and 
CU-OP-2, from 1 to 10 (Fig. S4A and B, respectively).
Changes in gene expression in HPV+ and HPV‑ 
OPSCC cell lines after IR with 2 Gy. The RNA-sequencing 
data was also examined to determine whether there were 
consistent differences in response to IR between the HPV+ and 
HPV- cell lines. An unsupervised analysis comparing treated 
and untreated cells was initially performed. After correction 
for multiple testing, 519 transcripts or genes were indicated as 
significant (data not shown). This indicated 2 Gy had a signifi-
cant effect on transcription of multiple genes. The top 19 genes 
with significant differences after treatment of the OPSCC lines 
with 2 Gy are presented in Table SI. None of the genes however, 
showed an obvious link to DNA repair, DNA damage or stress 
mechanisms, while transcription of the HPV oncogenes, E6 
and E7, was noted in all HPV+ cell lines (data not shown).
Figure 2. Distribution of cells in G1, S-phase and G2 at different time points after ionizing irradiation (2 and 6 Gy) for HPV+ cell lines: (A) UM-SCC-47, 
(B) UPCI‑SCC‑90, (C) CU‑OP‑2, (D) CU‑OP‑20 and (E) CU‑OP‑3. All indicated statistical significance values in the figure apply only to cells in G2 phase. 
The statistics present visually the significance between the untreated G2 phase and the treated G2 phases at the presented time points (*P<0.05, **P<0.01, 
***P<0.01 and ****P<0.001). Untreated samples presented represent time zero. N/A, not available; ns, not signifcant. All other statistical differences for G1 and 
S are presented in the text of the results section. HPV, human papillomavirus.
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Discussion
The present study investigated responses to ionising irradia-
tion (IR) in five human papillomavirus‑positive (HPV+) and five 
HPV- oropharyngeal squamous cell carcinoma (OPSCC) cell 
lines. Clonogenic survival assays, flow cytometry and RNA 
sequencing were used to assess survival, cell cycle distribution 
and HPV integration. We also report derivation and characteri-
sation of two novel OPSCC cell lines. HPV+ OPSCC cell lines 
showed greater variation in radiosensitivity than was apparent 
among the HPV- cell lines, and we observed a tendency for 
greater sensitivity to IR in HPV+ lines, although the correlation 
between radiosensitivity and HPV status was not perfect. HPV+ 
cells more frequently demonstrated an increase in G2 arrest 
following IR as compared to the HPV- OPSCC cell lines. It 
was interesting and potentially clinically relevant to note that 
radiation treatment resulted in a marked increase in novel HPV: 
Human fusion transcripts, which may suggest that radiation 
could facilitate integration of HPV DNA into novel genomic 
sites. However, due to the limited number of available cell lines 
and without further studies, a definite conclusion cannot be 
made after the current study. RNA sequencing did not indicate 
major changes in transcription of genes associated with DNA 
repair, DNA damage or stress mechanisms.
Following irradiation of HPV+ cell lines (UM-SCC-47, 
UPCI-SCC-90, CU-OP-2, CU-OP-3, and CU-OP-20) and 
the HPV- cell lines (UM-SCC-6, UM-SCC-4, UM-SCC-19, 
UM-SCC-74a and CU-OP-17), our observations show some 
Figure 3. Distribution of cells in the G1, S-phase and G2 at different time points after ionizing irradiation of HPV- cell lines with 2 and 6 Gy: (A) UM-SCC-19, 
(B) UM‑SCC‑6, (C) UM‑SCC‑4, (D) UM‑SSC‑74a and (E) CU‑OP‑17. All indicated statistical significance values in the figure apply only to cells in G2 phase. 
The statistics present visually the significance between the untreated G2 phase and the treated G2 phases at the presented time points (*P<0.05 and **P<0.01). 
Untreated samples presented represent time zero. ns, not signifcant. All other statistical differences for G1 and S are presented in the text of the results section. 
HPV, human papillomavirus.
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important differences from earlier reports (11-13). These 
data are based on an expanded panel of cell lines, since three 
more HPV+ and two HPV- OPSCC cell lines (HPV+ CU-OP-2, 
CU-OP-3, CU-OP-20 and HPV- CU-OP-17 and UM-SCC-74a) 
were added to the previously relatively limited panel of IR tested 
OPSCC cell lines (11‑18). Notably, in this report we did not find 
that HPV+ OPSCC cell lines were consistently and significantly 
more sensitive to IR relative to HPV- OPSCC cells (11-13), 
although this trend was evident in a limited number of lines. 
We suggest that it would be more accurate to state that HPV+ 
OPSCC cell lines show wider variation in radio-sensitivity than 
is observed among the HPV- OPSCC cell lines.
The wider variability in sensitivity to IR in the HPV+ group 
is in line with one previous report, where the authors also 
therefore suggest caution in de‑intensification of therapy via 
dose reduction (13). An example of this in the present study 
was that the HPV+ CU-OP-2 and CU-OP-3 cell lines were rela-
tively radioresistant as compared to the other HPV+ cell lines.
Of note, the HPV+ CU-OP-20, which according to our 
circos plots lacked major integrated HPV sites, was among the 
most radiosensitive HPV+ OPSCC cell line. The data are of 
course very limited, but would be consistent with suggestions 
that HPV+ OPSCC with episomal HPV DNA may have an even 
better prognosis (27,28).
Similar to other publications, we found that upon IR the 
proportion of HPV+ cell lines often exhibited an increase in G2 
arrest as compared to HPV- OPSCC lines, while changes in the 
proportion of cells in G1 and S-phase were not as apparent for any 
of the OPSCC cell lines (11-13). In two of the previous studies it 
was hypothesised that due to HPV16 E6-mediated degradation of 
p53, a greater G2 arrest should be expected in the HPV+ OPSCC 
cell lines (12,13). Notably, an increase in G2 arrest was the case 
for the HPV+ OPSCC cell lines in this study, irrespective as to 
whether the cell lines were radiosensitive or radioresistant. The 
data would still be in line with the hypothesis above indicating 
that it is due to HPV16 E6-mediated degradation of p53 rather 
than a correlation to radiosensitivity per se (12,13). This would 
be consistent with the observation that the most radiosensitive 
line, UM-SCC-47, and the most radioresistant CU-OP-3 were 
the two cell lines with the highest proportion of G2 arrest. To 
our knowledge this has not been demonstrated before. In fact, in 
an earlier report the numbers of cells arrested in G2 correlated 
to the radiosensitivity of the HPV+ OPSCC cell lines (13). The 
differences in the data reported between the present study and 
the study by Rieckmann et al (13) reflects the difficulties in 
drawing generalised conclusions on limited numbers of HPV+ 
OPSCC cell lines.
In this study, we also demonstrated an increase in HPV 
minor integration sites upon IR. We suggest that this could 
be due to an increase in DNA lesions following IR, and that 
this promotes integration of HPV DNA (possibly previously 
episomal) into new genomic locations.
mRNA sequencing IR treated and untreated cells also 
allowed investigation of changes in transcription of genes corre-
lated to DNA repair, cell cycle arrest and apoptosis. Our data did 
not indicate an increase in transcription of specific DNA repair 
genes after IR, which could be interpreted as consistent with 
the suggestion that the IR sensitivity of HPV+ OPSCC cell lines 
could be due to impaired capability to repair double-stranded 
DNA breaks (13). However, it may equally reflect the limitation 
of an experiment involving a single dose at a single time point. 
Other factors may better explain the better prognosis of HPV+ 
OPSCC patients. One report suggests e.g. that IR increases the 
levels of MHC class I in HPV+ OPSCC, thereby allowing for 
better immune recognition, while another study implies the 
necessity of an immune system to benefit from IR or chemo-
therapy (29,30). The role of CD47 has also been investigated, 
showing that this protein is downregulated upon IR, and that 
this in turn enhances immune recognition of HPV+ OPSCC (31).
There are limitations inherent in our study; only 10 OPSCC 
cell lines were assessed. Nonetheless this is a larger sample 
than investigated in several previous studies. By including 
five OPSCC cell lines previously not tested with IR, we could 
show a tendency, but not a significantly increased sensitivity to 
IR in HPV+ as compared to HPV- OPSCC cell lines, and this 
may challenge a previous dogma (12,13). Nevertheless, caution 
is still warranted to draw any major conclusions, since the 
numbers of cell lines in each category were limited.
Furthermore as already mentioned, another limitation 
was the special focus on one irradiation dose 2 Gy. However, 
we could confirm that upon IR, the proportion of cells in G2 
increased much more in HPV+ OPSCC cell lines as compared 
to HPV- OPSCC, but in this study the increase in G2 was 
not correlated to radiosensitivity as reported previously (13). 
Whether this is due to unique features of the CU-OP-3 cell line, 
or whether caution should be exercised in regarding G2 arrest 
as a measure of radiosensitivity, remains to be established.
To summarise, in this report five HPV+ and five HPV- 
OPSCCs cell lines, including five lines not previously assessed, 
were examined for radiosensitivity. HPV+ OPSCC lines 
demonstrated a wide range of sensitivity to IR, and impor-
tantly not all cell lines were radiosensitive, although they still 
tended to be more sensitive to irradiation than HPV- OPSCC 
lines. Furthermore, upon IR, HPV+ OPSCCs more often 
increased the proportion of cells in G2 arrest as compared to 
HPV- OPSCC cell lines, but the increases in G2 arrest were not 
correlated to radiosensitivity. Lastly, upon treatment with 2 Gy 
some increases in minor HPV integration sites were noted 
and changes in gene expression were demonstrated, but not in 
genes primarily associated with DNA repair.
To conclude, our data suggest that HPV+ OPSCC cell lines 
may possibly vary more in radiosensitivity than previously 
anticipated, and despite they are generally more sensitive than 
HPV- OPSCC cell lines, individual variations may exist within 
both the HPV+ and the HPV- OPSCC groups. Furthermore, 
in spite of the fact that 10 cell lines were tested, the data are 
limited and additional studies are warranted.
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